newsfilter
← Latest News
GlobeNewswire·

Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company

  • Dr. Eric Hughes, Executive Vice President of Global R&D & Chief Medical Officer at Teva, has resigned and accepted an offer outside the company.
  • Dr. Hughes will remain with Teva for the coming months to ensure a seamless transition.
  • David Gardiner, MD, Head of Innovative Medicines & Clinical Development, is the interim transition lead for R&D reporting directly to CEO Richard Francis.
  • Teva has initiated a comprehensive search for a permanent successor to Dr. Hughes immediately.
  • CEO Richard Francis stated that Teva's strategy, priorities, & expectations remain unchanged following the departure.
  • Dr. Hughes expressed pride in the R&D organization's contributions to establishing Teva as an innovative biopharma company.
  • Teva's R&D strategy remains focused on the commitments made during its November 11th R&D Day.
  • The company maintains its ambition to generate $6–7 billion in innovative medicines revenue by 2030.
  • Teva is a global biopharmaceutical company with over 120 years of history, specializing in generics, biosimilars, neuroscience, & immunology.
Company
Teva Pharmaceutical Industries Ltd
Keywords
NYSE:TEVA, Teva Pharmaceutical Industries Ltd